Moderna (MRNA) stock: analyst price target and their real reliability
Live quote · data updated Aug 28, 2026
Moderna · Health Care · ref. ETF XLV · 50 calls · price $142.77
What the company does: Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
📈 Moderna (MRNA) stock price
$142.77+483.4% over range
Aug 28, 25low $22.36 · high $174.38Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
17% recommend buying · 12 analysts
📊 JPI status :
Moderna is part of our 2026 selection (JPI Risk +), bought at the start of the year and tracked live. It no longer shows in today's ranking: its target has been reached, there is no gap left. See the 2026 selection and its performance →
⚠️ The stock trades above the median target: it has beaten expectations. The “Hold” reflects conviction on the company, but the remaining quantified upside is low/negative.
🎯 MRNA price target & analyst consensus — price $143
The price target · all analysts combined (10 targets)
Highest target · 1 firm of 10$150+5.1%
Median target · of 10 targets$77-46.1%
Lowest target · 1 firm of 10$38-73.4%
Current price$142.77
Where these 10 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price
110%
$150
Below
990%
$38 ↔ $125
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (825 calls tested). It aims for $89 (-38 %), call made on August 21, 2026, maturing on August 21, 2027 (7 d ago).
The 8 reliable analysts
$83-42 %
The 2 other firms
$47.50-67 %
How to read it: the 8 reliable firms are not filtered by optimism — 1 aim above the price, 7 below, hence their $83 median. “The 2 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 12 ratings (last 6 months)
Strong Buy00%
Buy217%
Hold867%
Sell217%
Strong Sell00%
Go deeper on the analysts
🎯 MRNA price target all
All 14 calls, one by one, with our verdict on each firm.
→ See all 14 targets, analyst by analyst💡 The best analysts on MRNA most reliable
The case for and against, with the numbers, per those who've been right on the stock.
→ Should you invest in MRNA? The case for & againstAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Moderna? The JPI assistant answers using our backtest data.
📈 Moderna fundamentals: valuation, margins & growth › open the full page
P/E —Net margin -141.4 %Revenue growth +2.1 %Not (yet) profitable
Revenue, net income and margin per year
Revenue Net income · hover a bar for details
2022
marg. 43 %
2023
Rev −64%Profit −156%
2024
Rev −53%
2025
Rev −40%
🔎 Detailed analyses
🏛️ Which US Congress members hold Moderna (MRNA)?
3 Congress members have disclosed MRNA buys. Click a highlighted name to see their track record (do they beat the S&P 500?).
✅ Historical analyst reliability on MRNA
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| Needham ↗ | 100% | +329.7% | 2 |
| BMO Capital ↗ | 100% | +207.4% | 2 |
| Morgan Stanley ↗ | 100% | +161.5% | 4 |
| SVB Leerink | 64% | -64.3% | 11 |
| Chardan Capital | 62% | +123.6% | 8 |
| JP Morgan ↗ | 60% | -1.6% | 5 |
| Brookline Capital | 50% | +112.6% | 2 |
| Deutsche Bank ↗ | 50% | +8.6% | 4 |
| Wolfe Research ↗ | 50% | +0.9% | 2 |
| UBS ↗ | 50% | -2.8% | 6 |
See the other 10 firms
| RBC Capital ↗ | 0% | -55.8% | 9 |
| TD Cowen ↗ | 0% | -14.2% | 2 |
| Goldman Sachs ↗ | 17% | -8.5% | 6 |
| Piper Sandler ↗ | 20% | -28.5% | 10 |
| B of A Securities ↗ | 25% | -19.9% | 4 |
| Argus Research ↗ | 25% | +4.5% | 4 |
| HSBC ↗ | 33% | +9.2% | 3 |
| Barclays ↗ | 33% | +14.7% | 6 |
| Jefferies ↗ | 33% | +32.5% | 3 |
| Oppenheimer ↗ | 40% | +22.9% | 5 |
📊 What $1,000 invested in Moderna would be worth › open the full page
In short — $1,000 invested in Moderna 10 years ago would be worth $3,765 today, i.e. +18%/yr on average. Best year: 2020 (+453%), worst: 2024 (-58%). Price performance, excluding dividends.
If I'd invested $1,000 in Moderna
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $1,660 | +66% |
| 3 years ago | $390 | -61% |
| 5 years ago | $670 | -33% |
Return by year (Moderna)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | +127% | $2,269 (+127%) |
| 2025 | -27% | $1,660 (+66%) |
| 2024 | -58% | $704 (-30%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Moderna
Loading news…
📋 All analyst calls on MRNA
Filtered on — · ✕ show all
Wolfe Research ↗
Aug 25, 26
■ Peer Perform neutral · not a buy
🎯 on MRNA : no call matured yet · 📊 on Health : 60.9% · +4.3% (46 calls)
in progress (365j)
matures : Aug 25, 27
matures : Aug 25, 27
■ Equal-Weight neutral · not a buy · 🎯$125
Price at call : $158.83 — gap to target -21%
Today : $142.77 — gap to target -12%
🎯 on MRNA : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Aug 24, 27
matures : Aug 24, 27
▼ Underweight · 🎯$77
Price at call : $138.89 — upside -45%
Today : $142.77 — upside -46%
🎯 on MRNA : 0% (2 calls matureds) · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Aug 21, 27
matures : Aug 21, 27
Goldman Sachs ↗
Aug 20, 26
■ Neutral neutral · not a buy · 🎯$120
Price at call : $145.13 — gap to target -17%
Today : $142.77 — gap to target -16%
🎯 on MRNA : no call matured yet · 📊 on Health : 50.8% · +2.0% (240 calls)
in progress (365j)
matures : Aug 20, 27
matures : Aug 20, 27
■ Neutral neutral · not a buy · 🎯$150
Price at call : $145.13 — gap to target +3%
Today : $142.77 — gap to target +5%
🎯 on MRNA : 100% (2 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Aug 20, 27
matures : Aug 20, 27
Morgan Stanley ↗
Aug 20, 26
■ Equal-Weight neutral · not a buy · 🎯$89
Price at call : $133.32 — gap to target -33%
Today : $142.77 — gap to target -38%
🎯 on MRNA : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Aug 20, 27
matures : Aug 20, 27
William Blair ↗
Aug 19, 26
▲ Outperform
🎯 on MRNA : no call matured yet · 📊 on Health : 63% · +5.2% (27 calls)
in progress (365j)
matures : Aug 19, 27
matures : Aug 19, 27
■ Neutral neutral · not a buy · 🎯$60
Price at call : $56.99 — gap to target +5%
Today : $142.77 — gap to target -58%
🎯 on MRNA : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Aug 3, 27
matures : Aug 3, 27
See the other 42 calls, newest to oldest
Goldman Sachs ↗
Jul 21, 26
■ Neutral neutral · not a buy · 🎯$67
Price at call : $59.66 — gap to target +12%
Today : $142.77 — gap to target -53%
🎯 on MRNA : no call matured yet · 📊 on Health : 50.8% · +2.0% (240 calls)
in progress (365j)
matures : Jul 21, 27
matures : Jul 21, 27
Morgan Stanley ↗
Jul 8, 26
■ Equal-Weight neutral · not a buy · 🎯$39
Price at call : $76.56 — gap to target -49%
Today : $142.77 — gap to target -73%
🎯 on MRNA : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Jul 8, 27
matures : Jul 8, 27
RBC Capital ↗
Jul 7, 26
■ Sector Perform neutral · not a buy · 🎯$45
Price at call : $73.8 — gap to target -39%
Today : $142.77 — gap to target -68%
🎯 on MRNA : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Jul 7, 27
matures : Jul 7, 27
B of A Securities ↗
Jul 7, 26
▼ Underperform · 🎯$38
Price at call : $73.8 — upside -49%
Today : $142.77 — upside -73%
🎯 on MRNA : 0% (2 calls matureds) · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Jul 7, 27
matures : Jul 7, 27
Piper Sandler ↗
Jun 26, 26
▲ Overweight · 🎯$77
Price at call : $69.7 — upside +10%
Today : $142.77 — upside -46%
🎯 on MRNA : no call matured yet · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Jun 26, 27
matures : Jun 26, 27
B of A Securities ↗
Jun 8, 26
▼ Underperform · 🎯$34
Price at call : $47.73 — upside -29%
Today : $142.77 — upside -76%
🎯 on MRNA : 0% (2 calls matureds) · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Jun 8, 27
matures : Jun 8, 27
■ Neutral neutral · not a buy · 🎯$45
Price at call : $46.71 — gap to target -4%
Today : $142.77 — gap to target -68%
🎯 on MRNA : 100% (2 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : May 4, 27
matures : May 4, 27
Goldman Sachs ↗
May 4, 26
■ Neutral neutral · not a buy · 🎯$49
Price at call : $46.71 — gap to target +5%
Today : $142.77 — gap to target -66%
🎯 on MRNA : no call matured yet · 📊 on Health : 50.8% · +2.0% (240 calls)
in progress (365j)
matures : May 4, 27
matures : May 4, 27
Evercore ISI Group ↗
May 4, 26
■ In-Line neutral · not a buy · 🎯$50
Price at call : $46.71 — gap to target +7%
Today : $142.77 — gap to target -65%
🎯 on MRNA : no call matured yet · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : May 4, 27
matures : May 4, 27
RBC Capital ↗
May 4, 26
■ Sector Perform neutral · not a buy · 🎯$38
Price at call : $46.71 — gap to target -19%
Today : $142.77 — gap to target -73%
🎯 on MRNA : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : May 4, 27
matures : May 4, 27
■ Equal-Weight neutral · not a buy · 🎯$48
Price at call : $48.77 — gap to target -2%
Today : $142.77 — gap to target -66%
🎯 on MRNA : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Apr 2, 27
matures : Apr 2, 27
Piper Sandler ↗
Feb 23, 26
▲ Overweight · 🎯$69
Price at call : $50.29 — upside +37%
Today : $142.77 — upside -52%
🎯 on MRNA : no call matured yet · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Feb 23, 27
matures : Feb 23, 27
Goldman Sachs ↗
Feb 17, 26
■ Neutral neutral · not a buy · 🎯$41
Price at call : $46.6 — gap to target -12%
Today : $142.77 — gap to target -71%
🎯 on MRNA : no call matured yet · 📊 on Health : 50.8% · +2.0% (240 calls)
in progress (365j)
matures : Feb 17, 27
matures : Feb 17, 27
RBC Capital ↗
Feb 17, 26
■ Sector Perform neutral · not a buy · 🎯$30
Price at call : $46.6 — gap to target -36%
Today : $142.77 — gap to target -79%
🎯 on MRNA : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Feb 17, 27
matures : Feb 17, 27
Evercore ISI Group ↗
Feb 17, 26
■ In-Line neutral · not a buy · 🎯$35
Price at call : $46.6 — gap to target -25%
Today : $142.77 — gap to target -75%
🎯 on MRNA : no call matured yet · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Feb 17, 27
matures : Feb 17, 27
Morgan Stanley ↗
Dec 12, 25
■ Equal-Weight neutral · not a buy · 🎯$28
Price at call : $29.92 — gap to target -6%
Today : $142.77 — gap to target -80%
🎯 on MRNA : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Dec 12, 26
matures : Dec 12, 26
■ Hold neutral · not a buy · 🎯$30
Price at call : $29.46 — gap to target +2%
Today : $142.77 — gap to target -79%
🎯 on MRNA : no call matured yet · 📊 on Health : 50.8% · +4.5% (380 calls)
in progress (365j)
matures : Dec 12, 26
matures : Dec 12, 26
Piper Sandler ↗
Nov 21, 25
▲ Overweight · 🎯$63
Price at call : $24.15 — upside +161%
Today : $142.77 — upside -56%
🎯 on MRNA : no call matured yet · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Nov 21, 26
matures : Nov 21, 26
RBC Capital ↗
Nov 21, 25
■ Sector Perform neutral · not a buy · 🎯$25
Price at call : $24.15 — gap to target +4%
Today : $142.77 — gap to target -82%
🎯 on MRNA : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Nov 21, 26
matures : Nov 21, 26
Leerink Partners ↗
Nov 21, 25
▼ Underperform · 🎯$18
Price at call : $24.15 — upside -25%
Today : $142.77 — upside -87%
🎯 on MRNA : 0% (1 call matured) · 📊 on Health : 55.3% · -4.8% (38 calls)
in progress (365j)
matures : Nov 21, 26
matures : Nov 21, 26
B of A Securities ↗
Nov 10, 25
▼ Underperform · 🎯$21
Price at call : $24.76 — upside -15%
Today : $142.77 — upside -85%
🎯 on MRNA : 0% (2 calls matureds) · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Nov 10, 26
matures : Nov 10, 26
■ Equal-Weight neutral · not a buy · 🎯$25
Price at call : $24.76 — gap to target +1%
Today : $142.77 — gap to target -82%
🎯 on MRNA : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Nov 7, 26
matures : Nov 7, 26
▲ Buy · 🎯$40
Price at call : $26.74 — upside +50%
Today : $142.77 — upside -72%
🎯 on MRNA : 100% (2 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Oct 23, 26
matures : Oct 23, 26
▼ Underweight · 🎯$25
Price at call : $26.74 — upside -7%
Today : $142.77 — upside -82%
🎯 on MRNA : 0% (2 calls matureds) · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Oct 23, 26
matures : Oct 23, 26
■ Neutral neutral · not a buy · 🎯$28
Price at call : $26.25 — gap to target +7%
Today : $142.77 — gap to target -80%
🎯 on MRNA : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Oct 23, 26
matures : Oct 23, 26
■ Hold neutral · not a buy
🎯 on MRNA : no call matured yet · 📊 on Health : 50.3% · +4.1% (155 calls)
in progress (365j)
matures : Oct 20, 26
matures : Oct 20, 26
Morgan Stanley ↗
Oct 10, 25
■ Equal-Weight neutral · not a buy · 🎯$32
Price at call : $26.74 — gap to target +20%
Today : $142.77 — gap to target -78%
🎯 on MRNA : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Oct 10, 26
matures : Oct 10, 26
Leerink Partners ↗
Aug 22, 25
▼ Underperform · 🎯$15
Price at call : $25.35 — upside -41%
Today : $142.77 — upside -89%
Expected -41% · Actual +448% · Reason (≤ −15%) : ✗ No
🎯 on MRNA : 0% (1 call matured) · 📊 on Health : 55.3% · -4.8% (38 calls)
-447.9%
stock +448% · XLV +28%
matured Aug 22, 26
■ Equal-Weight neutral · not a buy · 🎯$31
Price at call : $27.47 — gap to target +13%
Today : $142.77 — gap to target -78%
🎯 on MRNA : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Aug 4, 26
matures : Aug 4, 26
B of A Securities ↗
Jul 22, 25
▼ Underperform · 🎯$25
Price at call : $34.67 — upside -28%
Today : $142.77 — upside -82%
Expected -28% · Actual +64% · Reason (≤ −15%) : ✗ No
🎯 on MRNA : 0% (2 calls matureds) · 📊 on Health : 48.3% · +2.0% (356 calls)
-64.5%
stock +64% · XLV +18%
matured Jul 22, 26
▼ Underweight · 🎯$26
Price at call : $26.26 — upside -1%
Today : $142.77 — upside -82%
Expected -1% · Actual +79% · Reason (≤ −15%) : ✗ No
🎯 on MRNA : 0% (2 calls matureds) · 📊 on Health : 53.8% · +5.3% (355 calls)
-79.1%
stock +79% · XLV +14%
matured May 22, 26
▲ Buy · 🎯$70
Price at call : $27.84 — upside +151%
Today : $142.77 — upside -51%
Expected +151% · Actual +70% · Reason (≥ +15%) : ✓ Yes
🎯 on MRNA : 100% (2 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
+69.9%
stock +70% · XLV +5%
matured May 3, 26
■ Equal-Weight neutral · not a buy · 🎯$40
Price at call : $27.84 — gap to target +44%
Today : $142.77 — gap to target -72%
🎯 on MRNA : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : May 2, 26
matures : May 2, 26
RBC Capital ↗
May 2, 25
■ Sector Perform neutral · not a buy · 🎯$28
Price at call : $27.84 — gap to target +1%
Today : $142.77 — gap to target -80%
🎯 on MRNA : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : May 2, 26
matures : May 2, 26
Evercore ISI Group ↗
May 2, 25
■ In-Line neutral · not a buy · 🎯$32
Price at call : $27.61 — gap to target +16%
Today : $142.77 — gap to target -78%
🎯 on MRNA : no call matured yet · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : May 2, 26
matures : May 2, 26
Morgan Stanley ↗
Apr 9, 25
■ Equal-Weight neutral · not a buy · 🎯$32
Price at call : $24.5 — gap to target +31%
Today : $142.77 — gap to target -78%
🎯 on MRNA : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Apr 9, 26
matures : Apr 9, 26
▼ Underweight · 🎯$33
Price at call : $34.17 — upside -3%
Today : $142.77 — upside -77%
Expected -3% · Actual +50% · Reason (≤ −15%) : ✗ No
🎯 on MRNA : 0% (2 calls matureds) · 📊 on Health : 53.8% · +5.3% (355 calls)
-50.1%
stock +50% · XLV -2%
matured Mar 21, 26
■ Neutral neutral · not a buy · 🎯$40
Price at call : $34.62 — gap to target +16%
Today : $142.77 — gap to target -72%
🎯 on MRNA : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Mar 13, 26
matures : Mar 13, 26
▲ Buy · 🎯$78
Price at call : $33.73 — upside +131%
Today : $142.77 — upside -45%
Expected +131% · Actual +48% · Reason (≥ +15%) : ✓ Yes
🎯 on MRNA : 100% (2 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
+47.9%
stock +48% · XLV +7%
matured Feb 19, 26
RBC Capital ↗
Feb 18, 25
■ Sector Perform neutral · not a buy · 🎯$40
Price at call : $35.9 — gap to target +11%
Today : $142.77 — gap to target -72%
🎯 on MRNA : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Feb 18, 26
matures : Feb 18, 26
■ Equal-Weight neutral · not a buy · 🎯$45
Price at call : $35.75 — gap to target +26%
Today : $142.77 — gap to target -68%
🎯 on MRNA : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Feb 18, 26
matures : Feb 18, 26
B of A Securities ↗
Feb 11, 25
▼ Underperform · 🎯$34
Price at call : $30.93 — upside +10%
Today : $142.77 — upside -76%
Expected +10% · Actual +31% · Reason (≤ −15%) : ✗ No
🎯 on MRNA : 0% (2 calls matureds) · 📊 on Health : 48.3% · +2.0% (356 calls)
-31.0%
stock +31% · XLV +7%
matured Feb 11, 26
Frequently asked questions
Should I buy Moderna stock?
This isn't buy advice. For Moderna, the analyst consensus is "Hold", with an average price target of $77.00 (-46% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (2 calls tracked on Moderna). We show the numbers — you decide.
Is it too late to buy Moderna? How high can it go?
The most bullish analyst target on Moderna is $150 (+5% above today's price); the average is $77.00. That's the upside they see. Check how reliable those analysts have actually been on Moderna on our site before trusting it.
Is Moderna still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 20 analysts have a real record on Moderna, the best hitting 100% over 2 calls. Current consensus: "Hold". Make your call on data, not noise.
Should you invest in Moderna? The case for and against
The arguments for and against, one by one, from the numbers: why invest in MRNA (and why hesitate).
What has Moderna's past performance been?
Historical returns and a "how much if I had invested" calculator: MRNA performance & returns.
BIIB 
VRTX 
UNH 
REGN 
EW 
SRPT 
VEEV 
BSX